Status:
COMPLETED
Impact of Time to Re-staging Transurethral Resection on Recurrence and Progression Rates
Lead Sponsor:
Saglik Bilimleri Universitesi
Conditions:
Bladder Cancer
Eligibility:
All Genders
44-86 years
Phase:
NA
Brief Summary
Purpose To investigate the significance of time to re-staging transurethral resection (re-TUR) on recurrence and progression rates in patient with high-risk non-muscle-invasive bladder cancer. Method...
Detailed Description
This study was performed between August 2016 and December 2020 after obtaining the approval of local ethics committee (0651-5479). Patients diagnosed with primary high risk non-muscle-invasive bladder...
Eligibility Criteria
Inclusion
- Patients with a tumor pathology other than transitional cell carcinoma, incomplete resection at initial TUR, who cannot complete 1 year of maintenance BCG treatment, did not attend their regular cystoscopic control or wanted to leave from the study voluntarily and lastly, with a diagnosis of muscle-invasive cancer on re-TUR were excluded.
Exclusion
- Inclusion criteria were having a high grade Ta or T1 transitional cell carcinoma with or without carcinoma in situ (CIS) after a complete initial TUR of bladder carcinoma, and receiving six weekly induction BCG therapy with at least 1 year maintenance.
Key Trial Info
Start Date :
August 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2020
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT04768894
Start Date
August 1 2016
End Date
December 10 2020
Last Update
February 26 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.